Introduction {#sec0005}
============

Since the first report[@bib0285] of Coronavirus Disease 2019 (COVID-19) in Wuhan, the causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has undergone rapid global spread within a matter of months. Due to the alarming rates of transmission, the World Health Organization officially declared the situation as a pandemic, with over 1.051.635 infections and 56,985 deaths worldwide per April 6th 2020.[@bib0290] The pandemic continues to place a major strain on a country\'s resources,[@bib0295] and it is predicted that mortality and morbidity rates will become pronounced with the rising spread amongst lower- and middle-income countries where healthcare is already at capacity.[@bib0300]

Pandemic management emphasizes on prompt identification and containment, achievable through strict surveillance and early diagnosis.[@bib0305], [@bib0310] Gold-standard diagnosis of COVID-19 is achieved through molecular identification of the SARS-CoV-2 using nucleic acid amplification tests such as the reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) or viral gene sequencing.[@bib0315] In some countries, rapid serological tests are also implemented to complement molecular diagnosis. However, many low resource settings are not equipped with sufficient laboratory and human resource capacity to perform massive molecular identification. The lack of resources in addition to long turnaround time leads to delays between testing and confirmation, during which clinical judgment is crucial. During this period, patient history, hematological and biochemical laboratory parameters, and imaging are necessary for aiding the diagnostic process. Another concerning feature of SARS-CoV-2 infection is the variable case presentation with alarming mortality rates in high-risk groups such as the elderly and immunocompromised.[@bib0320] Cases of COVID-19 that progress into severe and critical disease are marked with acute respiratory distress (ARDS) and multi-organ failure, requiring highly intensive care. In these scenarios, timely detection of disease progression is crucial for appropriate management and intervention.

In this meta-analysis, we aim to provide an evidence-based summary of the latest studies to (1) determine the differences between laboratory parameters in COVID-19 pneumonia and non-COVID-19 pneumonia, and (2) determine the differences between laboratory parameters in severe and non-severe COVID-19. This study focused on parameters that are routinely tested and readily available even in low-resource settings. The analysis encompasses hematological parameters (including total leukocyte, neutrophil, thrombocyte and lymphocyte counts), D-dimer, procalcitonin (PCT), and C-reactive protein (CRP) levels.

Methods {#sec0010}
=======

Literature search and data extraction {#sec0015}
-------------------------------------

This meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines.[@bib0325] A literature search was conducted from PubMed, Scopus, the Chinese Medical Journal Network, Google Scholar, and Web of Science. Keywords such as "COVID-19", "2019-nCOV", "SARS-COV-2", "novel coronavirus disease", "novel coronavirus pneumonia", non-COVID-19 pneumonia", and "severe COVID-19" were used singularly and in combination. No date, location, or language restrictions were applied during the literature search.

The literature search was updated until March 2020. The inclusion criteria were as follows: (1) primary research reports of COVID-19 infection with cumulative or raw laboratory values (2) case-control or cohort study, (3) studies with matched controls (COVID-19 versus non-COVID-19 pneumonia and severe versus non-severe COVID-19). Data were extracted as follows: (1) name of the first author, (2) year of publication, (3) country and city of study origin, (4) number of COVID-19 pneumonia (PCR positive) and non-COVID-19 pneumonia (PCR negative), (5) number of severe (i.e., ICU admission, those needing mechanical ventilation, or those who died), and non-severe COVID-19 cases (6) the mean and median of laboratory parameters of the patients.

Data synthesis and statistical analysis {#sec0020}
---------------------------------------

To assess the difference between parameters measured in COVID-19 and non-COVID-19 patients or severe and non-severe cases, pooled standardized mean difference (SMD) with 95% confidence interval (CI) was used. Heterogeneity among studies was evaluated using Q test and *I* ^2^ statistic. A significant Q-statistic (*p*  \< 0.10) indicated heterogeneity across studies. The *I* ^2^ values indicated no (0--24.9%), low (25--49.9%), moderate (50--74.9%) or high (75--100%) heterogeneity. The random-effect model (REM) was used if heterogeneity existed; otherwise, the fixed-effect model (FEM) was used. Begg\'s funnel plot and Egger\'s regression test were applied to determine publication bias if the pooled effect size consisted of 10 or more studies.[@bib0330] A sensitivity test was performed by sequentially omitting one study each time to evaluate the stability of the results. Data that were not expressed as mean and standard deviation were extrapolated according to Hozo et al. and Wan et al.[@bib0335], [@bib0340]

Meta-analysis was performed using RevMan ver 5.3. Statistical tests were 2-sided and used a significance threshold of *p*  \< 0.05. The mean values of parameters that were found to be significant in the meta-analysis were then used to generate receiver-operating-characteristic (ROC) curves using Graphpad Prism ver 8.1.2 in order to determine the area under the curve (AUC). The optimal cutoff for parameters with a significant *p*-value (two-sided) were determined using the Youden\'s index,[@bib0345], [@bib0350] and the corresponding sensitivity and specificity for the cut-off was also calculated.

Results {#sec0025}
=======

Laboratory parameters in COVID-19 and non-COVID-19 cases {#sec0030}
--------------------------------------------------------

In the literature search, a total of 50 articles were retrieved from databases. After reviewing the title and abstract, 42 articles were excluded on the basis of duplications, being a review article, or if the study did not classify cases into COVID-19 and non-COVID-19 infection. Finally, only 7 studies were included in this meta-analysis ([Fig. 1](#fig0010){ref-type="fig"} ).[@bib0355], [@bib0360], [@bib0365], [@bib0370], [@bib0375], [@bib0380], [@bib0385] The characteristics of included studies are shown in [Supplemental Table 1](#sec0065){ref-type="sec"}. In general, the pooled studies showed high heterogeneity, except for leukocyte and neutrophil values ([Table 1](#tbl0005){ref-type="table"} ). Interestingly, we found that leukocyte, neutrophil, and thrombocyte counts were significantly lower in COVID-19 than in non-COVID-19 cases (SMD = −0.42, 95%CI −0.60 to −0.25, *p*  \< 0.00001 ([Fig. 2](#fig0015){ref-type="fig"} A); SMD = −0.23, 95%CI −0.41 to −0.06, *p*  = 0.01 ([Fig. 2](#fig0015){ref-type="fig"}B); SMD = −0.54, 95%CI −0.91 to −0.16, *p*  = 0.0005 ([Fig. 2](#fig0015){ref-type="fig"}C), respectively). No significant difference in other parameters were observed between the two groups ([Table 1](#tbl0005){ref-type="table"}). A sensitivity analysis conducted by eliminating one individual study each time (data not shown), showed no change in the pooled analyses, implying the statistical stability of the findings. The ROC curve of crucial parameters is shown in [Fig. 2](#fig0015){ref-type="fig"}D, demonstrating that thrombocyte count provides good discrimination (AUC = 0.88, *p*  = 0.04) between COVID-19 and non-COVID-19 pneumonia with an optimal cutoff of 188.4 × 10^9^/L, yielding a sensitivity of 80% and specificity of 100%.Fig. 1Flow diagram of the study selection process in this meta-analysis.Table 1Meta-analysis of laboratory findings between COVID-19 and Non-COVID-19 patients.Table 1ParametersNo. of cohortSample size (COVID-19/non-COVID-19)SMD95% CI*I*^2^ (%)Statistical method*p*Leukocyte (×10^9^/L)7189/474−0.42−0.60 to −0.2548FEM\<0.00001[\*](#tblfn0005){ref-type="table-fn"}Lymphocyte (×10^9^/L)7189/474−0.37−0.81 to −0.0778REM0.10Neutrophil (×10^9^/L)6170/468−0.23−0.41 to −0.0638FEM0.01[\*](#tblfn0005){ref-type="table-fn"}Thrombocyte (×10^9^/L)5168/427−0.54−0.91 to −0.1670REM0.005[\*](#tblfn0005){ref-type="table-fn"}D-dimer (μg/mL)263/107−0.27−0.59 to 0.060FEM0.11CRP (mg/L)6168/4160.29−0.33 to 0.9087REM0.35PCT (ng/mL)3136/338−0.44−1.20 to 0.3291REM0.26[^2][^3]Fig. 2Forest plot for pooled standardized mean difference (SMD) and 95% confidence interval (CI) of laboratory parameters in COVID-19 and non-COVID-19-infected patients; (A) leukocyte; (B) neutrophil; and (C) thrombocyte. (D) Receiver operating characteristics (ROC) curve of cell counts for the differentiation of COVID-19 and non-COVID-19 pneumonia.

Laboratory parameters in severe and non-severe COVID-19 cases {#sec0035}
-------------------------------------------------------------

A total of 475 potentially relevant studies were initially detected, 368 of which were excluded after title and abstract review and removing duplications. One hundred and seven studies were eligible for further screening. However, 81 articles were subsequently removed on the basis of (1) being either review articles and meta-analysis (*n*  = 11) or case reports (*n*  = 13) (2) inability to extract the data (*n*  = 33), or (3) did not classify the COVID-19 cases as a non-severe and severe condition (*n*  = 24). Thus, 26 studies were included in this meta-analysis ([Fig. 1](#fig0010){ref-type="fig"}).[@bib0295], [@bib0370], [@bib0390], [@bib0395], [@bib0400], [@bib0405], [@bib0410], [@bib0415], [@bib0420], [@bib0425], [@bib0430], [@bib0435], [@bib0440], [@bib0445], [@bib0450], [@bib0455], [@bib0460], [@bib0465], [@bib0470], [@bib0475], [@bib0480], [@bib0485], [@bib0490], [@bib0495], [@bib0500], [@bib0505] Details of the retrieved studies are shown in [Supplemental Table S2](#sec0065){ref-type="sec"}. Although the heterogeneity was considerably high in all parameters measured (*I* ^2^  = between 67 and 90%, ([Table 2](#tbl0010){ref-type="table"} ), we found that leukocytes, neutrophils, D-dimer, and CRP levels were significantly higher (SMD = 0.35, 95%CI 0.09--0.61, *p*  = 0.009 ([Fig. 3](#fig0020){ref-type="fig"} A); SMD = 0.50, 95%CI 0.28--0.72, *p*  \< 0.0001 ([Fig. 3](#fig0020){ref-type="fig"}B); SMD = 0.56, 95%CI 0.32--0.80, *p*  \< 0.00001 ([Fig. 4](#fig0025){ref-type="fig"} A); SMD = 0.99, 95%CI 0.69--1.29, *p*  \< 0.00001) ([Fig. 4](#fig0025){ref-type="fig"}B), respectively) in COVID-19 infected patients with severe condition than in those with non-severe condition. Contrastingly, lymphocyte and thrombocyte counts were significantly lower in severe COVID-19 infected patients (SMD = −0.57, 95%CI −0.73 to −0.40, *p*  \< 0.00001; SMD = −0.33, 95%CI −0.52 to −0.14, *p*  = 0.000; [Fig. 5](#fig0030){ref-type="fig"} A and B, respectively). No difference was observed in PCT levels ([Table 2](#tbl0010){ref-type="table"}). Begg\'s funnel plot ([Supplemental Fig. 1A--G](#sec0065){ref-type="sec"}) and Egger\'s test were performed revealing no publication bias ([Table 2](#tbl0010){ref-type="table"}). A sensitivity analysis was also performed (data not shown), revealing identical results, hence suggesting that the statistical stability and robustness of the findings.Table 2Meta-analysis of laboratory findings between severe and non-severe patients with COVID-19.Table 2ParametersNo. of cohortSample size (Severe/Non-Severe)SMD95% CI*I*^2^ (%)Statistical method*p*Publication bias (*p* Egger)Leukocyte (×10^9^/L)241119/28250.350.09 to 0.6190REM0.009[\*](#tblfn0010){ref-type="table-fn"}0.725Lymphocyte (×10^9^/L)241090/2832−0.57−0.73 to −0.4073REM\<0.00001[\*](#tblfn0010){ref-type="table-fn"}0.547Neutrophil (×10^9^/L)16675/12570.500.28 to 0.7272REM\<0.0001[\*](#tblfn0010){ref-type="table-fn"}0.892Thrombocyte (×10^9^/L)15624/2103−0.33−0.52 to −0.1467REM0.0006[\*](#tblfn0010){ref-type="table-fn"}0.840D-dimer (μg/mL or mg/L)14451/12050.560.32 to 0.8074REM\<0.00001[\*](#tblfn0010){ref-type="table-fn"}0.865CRP (mg/L)17737/12720.990.69 to 1.2985REM\<0.00001[\*](#tblfn0010){ref-type="table-fn"}0.112PCT (ng/mL)13596/10410.19−0.06 to 0.4475REM0.140.930[^4][^5]Fig. 3Forest plot for pooled standardized mean difference (SMD) and 95% confidence interval (CI) of laboratory parameters in severe and non-severe COVID-19-infected patients; (A) leukocyte and (B) neutrophil.Fig. 4Forest plot for pooled standardized mean difference (SMD) and 95% confidence interval (CI) of laboratory parameters in severe and non-severe COVID-19-infected patients; (A) D-dimer and (B) CRP.Fig. 5Forest plot for pooled standardized mean difference (SMD) and 95% confidence interval (CI) of laboratory parameters in severe and non-severe COVID-19-infected patients; (A) lymphocyte and (B) thrombocyte.

The ROC curves of the crucial blood cell count parameters are shown in [Fig. 6](#fig0035){ref-type="fig"} A, demonstrating that fair to good distinction of severe and non-severe COVID-19 was demonstrated by the neutrophil (AUC = 0.79, *p*  = 0.004), lymphocyte (AUC = 0.87, *p*  \< 0.0001), leukocyte (AUC = 0.69, *p*  = 0.019), and thrombocyte (AUC = 0.76, *p*  = 0.013) counts. The optimal cut-offs are 3.65 × 10^9^/L for neutrophil count (sensitivity = 75%, specificity = 81.2%), 0.83 × 10^9^/L for lymphocyte count (sensitivity = 72%, specificity = 96%), 5.3 × 10^9^/L for leukocyte count (sensitivity = 66.6%, specificity = 79.1%), and 170.8 × 10^9^/L for thrombocyte count (sensitivity = 66.6%, specificity = 80%). The ROC curve of crucial markers ([Fig. 6](#fig0035){ref-type="fig"}B), demonstrate that CRP provides better discrimination between severe and non-severe COVID-19 pneumonia relative to D-dimer (AUC = 0.88, *p*  = 0.0001 versus AUC = 0.77, *p*  = 0.02 respectively), with an optimal cutoff of 34.67 mg/L for CRP (sensitivity = 82.3%, specificity = 73%) and 0.44 μg/mL for D-dimer (sensitivity = 90.9%, specificity = 54.55%).Fig. 6Receiver operating characteristics (ROC) curve and optimal thresholds of significant laboratory parameters. (A) Blood cell counts for the differentiation of severe and non-severe COVID-19. (B) Markers for the differentiation of severe and non-severe COVID-19.

Discussion {#sec0040}
==========

Molecular identification of SARS-CoV-2 in low-resource settings remains centralized and time-consuming, resulting in a delayed diagnosis of COVID-19. The first analysis performed in this study aimed to summarize current evidence to identify frequently performed laboratory parameters that can assist in COVID-19 case identification. This revealed significantly lower leukocyte, neutrophil, and thrombocyte levels in COVID-19 patients compared to non-COVID-19 patients. Additionally, the pronounced variation in COVID-19 clinical presentation and outcome makes it imperative to predict potentially progressive cases. Hence, the second analysis of this study aimed to identify common laboratory parameters that can act as markers of severe infection, revealing a significant difference in the leukocyte, neutrophil, thrombocyte, and lymphocyte counts as well as D-dimer and CRP levels between severe and non-severe COVID-19 cases.

Relative to non-COVID-19 infections, significantly lower absolute leukocyte or neutrophil counts during early stages of the disease has been broadly demonstrated,[@bib0355], [@bib0370], [@bib0385] although the mean leukocyte count of the included studies often do not exceed the lower limit for categorisation as leukopenia or neutropenia. Interestingly, with COVID-19 disease progression, we found that both leukocyte and neutrophil counts were significantly higher in the severe groups in line with previous retrospective studies,[@bib0485] and other meta-analysis.[@bib0510] It has been previously established that reduction in circulating leukocytes and neutrophils commonly arise following viral invasion, as a consequence of either bone marrow suppression or peripheral destruction[@bib0515] during initial stages of infection. This may increase the susceptibility of secondary bacterial infections in severe COVID-19, a consequence that is often marked by leukocytosis. In a dynamic profile of laboratory results presented by Wang et al.,[@bib0485] non-surviving or severe COVID-19 cases showed steadily increasing levels of the two parameters, resulting in leukocytosis and neutrophilia that was significantly higher compared to the non-severe COVID-19 group, postulated to be a consequence of the secondary infection and infection-induced cytokine storm.

Limited studies have examined the role of the thrombocyte count in COVID-19 identification. In a previous meta-analysis,[@bib0520] thrombocytopenia has been implicated as a marker for severe SARS-CoV-2 infection. This study augments said findings, revealing that thrombocyte counts can also be used as a marker to differentiate between COVID-19 and non-COVID-19 infections, regardless of severity. In areas with concurrently high dengue infection rates such as South East Asia, the similarities between initial clinical and laboratory presentations of SARS-CoV-2 and dengue infection should be carefully considered during the current pandemic. A report from Singapore[@bib0525] have shown covert COVID-19 infection in patients originally suspected of dengue infection, with consistent thrombocytopenia observed in the two reported cases. Moreover, false positive dengue serology occurred in the two COVID-19 cases, further complicating the distinction and posing a risk to the intense surveillance required during the current pandemic.

The consistent finding of thrombocytopenia as a marker of severe COVID infection in this study with the aforementioned meta-analysis[@bib0520] by Lippi et al. further emphasizes that this low-cost and routinely-performed blood parameter can aid both diagnosis and monitoring of progression and should be assessed continually during care of COVID-19 infections. The mechanism behind thrombocytopenia in both early and late stages of COVID-19 infection is likely multifactorial, as a result of both indirect and direct mechanisms that interfere with thrombocyte production, activation, or consumption.[@bib0530] Although studies are required to confirm, it is highly probable that the mechanisms of SARS-CoV-2 induced thrombocytopenia are analogous to those previously characterized in the SARS-CoV, as both belong to the same family of coronaviruses. Possible direct mechanisms of thrombocytopenia previously characterized in the SARS-CoV is viral bone marrow invasion and infection of progenitor cells, therefore interfering with thrombocyte production from megakaryocytes by inhibition of growth and by inducing apoptosis.[@bib0535] Other potential mechanisms of thrombocytopenia include excess activation of thrombocytes by virus-triggered immune complexes, and increased consumption due to excessive thrombosis that occur during lung damage.[@bib0535]

Furthermore, extreme thrombocytopenia is often observed in severe and critical conditions of illness due to the development of disseminated intravascular coagulopathy (DIC), reflected excessive coagulation activity marked by significantly higher levels of D-dimers found in our analysis among patients of severe COVID-19 infection. This is in line with previous studies showing D-dimer as a marker for severe COVID-19,[@bib0430] and even as a marker of mortality at levels higher than 1 μg/L.[@bib0470], [@bib0540]

Several reports[@bib0355], [@bib0365], [@bib0370], [@bib0475], [@bib0545], [@bib0550] have suggested lymphopenia as a strong indicator of COVID-19 infection. In the first analysis however, despite a trend of lowered lymphocyte count in COVID-19 cases, no statistical significance was observed between the two groups. The possible reason for the insignificant difference between the pooled studies of both groups is that two studies[@bib0375], [@bib0385] included in the analysis showed higher tendency of lymphopenia to occur in the non-COVID group. However, in the second analysis lymphocyte counts were found significantly lower in the severe group, which is in line with previous reports which observed progressive lymphopenia[@bib0485] as a strong indicator of disease severity.

The results of the first analysis showed that both CRP and procalcitonin were not significant differentiators of COVID-19 and non-COVID-19 cases. However, in the second analysis, a significantly higher level of CRP was observed in the severe COVID-19 group compared to non-COVID-19 cases, confirming previous reports of the clinical utility of CRP levels as an indicator for severe disease and progressive inflammation.[@bib0405], [@bib0435], [@bib0480] In contrast to a previous meta-analysis,[@bib0555] procalcitonin level between severe and non-severe groups were not significantly different in this analysis, which pooled the procalcitonin results of 14 studies. The changes in procalcitonin level among severe COVID patients remain unclear, because although half[@bib0370], [@bib0420], [@bib0430], [@bib0445], [@bib0490], [@bib0505], [@bib0560] of the 14 analyzed studies showed an insignificant difference between procalcitonin levels between the two groups, the remaining seven analyzed studies reported significantly higher PCT values in the severe group. These reports postulate that raised PCT indicates the presence of secondary bacterial infection.

There are several limitations in our study. First, because of the novelty of the outbreak, the quantity and diversity of the studies are limited, with a bulk originating from various regions in China. Further investigation is required to verify the findings in more diverse geographical settings, and resource conditions. A high heterogeneity was also noted in this study, which may be due to discrepancies between the classification between severe and non-severe COVID-19 across studies, and the lack of data regarding the exact timing of laboratory data collection in the studies. Hence future investigations need to assess the time-sensitive changes in laboratory parameters. And although the follow-up ROC analysis in this study determined the most optimal diagnostic and prognostic markers, future studies should explore the predictive value of marker combinations in order to maximize the discriminatory capacity. Finally, we did not evaluate several other potential parameters such as eosinophil count,[@bib0360] due to the lack of data associated with such parameter in our collected studies.

Despite the aforementioned limitations, to our knowledge, this is the first analysis that examines laboratory parameters from two perspectives; (1) from a diagnostic perspective to determine parameters that can aid differentiation between COVID-19 and non-COVID-19 pneumonia, and (2) from a prognostic perspective to determine parameters that can aid differentiation between non-severe and severe COVID-19 cases. By inclusion of studies with raw mean data, we could avoid discrepancies that may occur because of varying cut-offs of laboratory parameters across studies.

Conclusion {#sec0045}
==========

In conclusion, thrombocyte count was significantly lower in COVID-19 compared to non-COVID-19 infections, and persistently low in severe disease, implying that thrombocyte measurement is a key laboratory parameter for both diagnosis and prognosis. Leukocyte and neutrophil counts were significantly lower in COVID-19 compared to non-COVID-19 infections, but contrastingly higher in severe COVID-19 cases relative to non-severe COVID-19. And although lymphocyte, D-dimer and CRP levels were not significantly different between COVID-19 and non-COVID-19 cases, all three are effective indicators for severe cases of COVID-19. As more studies become available, further analysis is required to confirm these findings.
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